As blocking of CD200 with the CD200 siRNA or sCD200R1 dramatically and consistently reversed its ability to promote EMT, therapeutic targeting of CD200 might be effective for treating patients with solid tumors such as HNSCC. This evidence concerns the gene CD200 and head and neck squamous cell carcinoma.